• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

先天性隆突性皮肤纤维肉瘤的外科治疗

Surgical management of congenital dermatofibrosarcoma protuberans.

作者信息

Love W Elliot, Keiler Susan A, Tamburro Joan E, Honda Kord, Gosain Arun K, Bordeaux Jeremy S

机构信息

Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio, USA.

出版信息

J Am Acad Dermatol. 2009 Dec;61(6):1014-23. doi: 10.1016/j.jaad.2009.05.028.

DOI:10.1016/j.jaad.2009.05.028
PMID:19925926
Abstract

Congenital dermatofibrosarcoma protuberans (DFSP) is a rare tumor with varying clinical presentations that is commonly misdiagnosed. Treatment of congenital DFSP is complicated by delays in diagnosis and its propensity for subclinical spread. Of 61 reported cases, 11 (18%) were treated with Mohs micrographic surgery (MMS) and 46 (75%) were treated with wide local excision (WLE). One case was treated with imatinib, and the remaining 3 did not differentiate between receiving MMS or WLE. In the cases of congenital DFSP treated with MMS the clearance rate was 100% with an average follow-up of 4.3 years. The clearance rate seen with WLE was 89% with an average follow-up period of 1.9 years. The average margins taken during MMS (1.7 cm) were smaller than those taken with WLE (2.8 cm). Fifty percent of cases with available follow-up undergoing WLE required multiple surgeries. Based on superior cure rates with long-term follow-up, smaller surgical margins, and fewer surgical sessions, MMS should be considered as first-line treatment for congenital DFSP.

摘要

先天性隆突性皮肤纤维肉瘤(DFSP)是一种临床表现各异的罕见肿瘤,常被误诊。先天性DFSP的治疗因诊断延迟及其亚临床扩散倾向而变得复杂。在61例报告病例中,11例(18%)接受了莫氏显微外科手术(MMS)治疗,46例(75%)接受了广泛局部切除(WLE)治疗。1例接受了伊马替尼治疗,其余3例未区分接受MMS还是WLE治疗。在接受MMS治疗的先天性DFSP病例中,清除率为100%,平均随访4.3年。WLE的清除率为89%,平均随访期为1.9年。MMS期间切除的平均切缘(1.7 cm)小于WLE(2.8 cm)。接受WLE治疗且有随访资料的病例中有50%需要多次手术。基于长期随访的更高治愈率、更小的手术切缘和更少的手术次数,MMS应被视为先天性DFSP的一线治疗方法。

相似文献

1
Surgical management of congenital dermatofibrosarcoma protuberans.先天性隆突性皮肤纤维肉瘤的外科治疗
J Am Acad Dermatol. 2009 Dec;61(6):1014-23. doi: 10.1016/j.jaad.2009.05.028.
2
Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery.隆突性皮肤纤维肉瘤:广泛局部切除与莫氏显微外科手术对比
Cancer Treat Rev. 2008 Dec;34(8):728-36. doi: 10.1016/j.ctrv.2008.06.002. Epub 2008 Aug 5.
3
Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature.隆突性皮肤纤维肉瘤:29例采用莫氏显微外科手术治疗患者的报告及长期随访与文献复习
Cancer. 2004 Jul 1;101(1):28-38. doi: 10.1002/cncr.20316.
4
Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution.隆突性皮肤纤维肉瘤手术后的低复发率:来自单一机构的多学科方法。
Cancer. 2004 Mar 1;100(5):1008-16. doi: 10.1002/cncr.20051.
5
Treatment of dermatofibroma sarcoma protuberans using modified Mohs micrographic surgery: no recurrences and smaller defects.采用改良莫氏显微外科手术治疗隆突性皮肤纤维肉瘤:无复发且缺损更小。
Dermatol Surg. 2008 Jun;34(6):780-4. doi: 10.1111/j.1524-4725.2008.34146.x. Epub 2008 Mar 3.
6
A Comparison of Mohs Micrographic Surgery and Wide Local Excision for Treatment of Dermatofibrosarcoma Protuberans With Long-Term Follow-up: The Mayo Clinic Experience.莫氏显微外科手术与广泛局部切除治疗隆突性皮肤纤维肉瘤的长期随访比较:梅奥诊所经验
Dermatol Surg. 2017 Jan;43(1):98-106. doi: 10.1097/DSS.0000000000000910.
7
Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans.广泛切除术或 Mohs 显微描记手术治疗原发性隆突性皮肤纤维肉瘤。
Am J Clin Oncol. 2010 Jun;33(3):300-3. doi: 10.1097/COC.0b013e3181aaca87.
8
Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: cure rates and surgical margins.用莫氏显微外科手术治疗隆突性皮肤纤维肉瘤:治愈率和手术切缘
Dermatol Surg. 1996 Jun;22(6):530-4.
9
The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans.莫氏显微外科手术相较于传统广泛局部切除手术治疗隆突性皮肤纤维肉瘤的疗效。
Pan Afr Med J. 2019 Aug 13;33:297. doi: 10.11604/pamj.2019.33.297.17692. eCollection 2019.
10
Dermatofibrosarcoma protuberans (DFSP): growth characteristics based on tumor modeling and a review of cases treated with Mohs micrographic surgery.隆突性皮肤纤维肉瘤(DFSP):基于肿瘤建模的生长特征及Mohs显微外科手术治疗病例回顾
Ann Plast Surg. 1997 Mar;38(3):246-51.

引用本文的文献

1
From skin to pancreas: The unusual path of fibrosarcomatous dermatofibrosarcoma protuberans - A rare case report.从皮肤到胰腺:隆突性皮肤纤维肉瘤的纤维肉瘤样不寻常病程——1例罕见病例报告
Int J Surg Case Rep. 2025 Jun;131:111337. doi: 10.1016/j.ijscr.2025.111337. Epub 2025 Apr 26.
2
Dermatofibrosarcoma protuberans: surgical management of a challenging mesenchymal tumor.隆突性皮肤纤维肉瘤:一种具有挑战性的间叶性肿瘤的外科治疗。
World J Surg Oncol. 2019 May 28;17(1):90. doi: 10.1186/s12957-019-1627-3.
3
Retiform hemangioendothelioma in the infratemporal fossa and buccal area: a case report and literature review.颞下窝及颊部的网状血管内皮瘤:一例报告并文献复习
J Korean Assoc Oral Maxillofac Surg. 2016 Oct;42(5):307-314. doi: 10.5125/jkaoms.2016.42.5.307. Epub 2016 Oct 25.
4
Wide Local Excision for Dermatofibrosarcoma Protuberans: A Single-Center Series of 90 Patients.隆突性皮肤纤维肉瘤的广泛局部切除:单中心90例患者系列研究
Biomed Res Int. 2015;2015:642549. doi: 10.1155/2015/642549. Epub 2015 Nov 25.
5
Dermatofibrosarcoma protuberans: Our experience of 59 cases.隆突性皮肤纤维肉瘤:我们59例病例的经验。
Oncol Lett. 2012 Nov;4(5):1047-1055. doi: 10.3892/ol.2012.887. Epub 2012 Aug 30.
6
Dermatofibrosarcoma protuberans of the scalp with fibrosarcomatous degeneration and pulmonary metastasis.头皮隆突性皮肤纤维肉瘤伴纤维肉瘤变性及肺转移
J Clin Imaging Sci. 2011;1:55. doi: 10.4103/2156-7514.90482. Epub 2011 Dec 2.
7
Status report on the management of dermatofibrosarcoma protuberans: is there a viable role for the use of imatinib mesylate? In which cases may it be therapeutically helpful and in which cases not?隆突性皮肤纤维肉瘤管理的现状报告:甲磺酸伊马替尼的使用是否有可行的作用?在哪些情况下它可能具有治疗帮助,而在哪些情况下没有?
J Clin Aesthet Dermatol. 2011 Mar;4(3):17-26.